Cutaneous reactions at the site of post-infection gp160 vaccination therapy in HIV-1 + patients

International Journal of Dermatology

Volumn 37, Issue 4, 1998, Pages 293-298

  Smith, Kathleen J ^a,d   Skelton, Henry G ^a   Ruiz, Nancy ^b   Samlaska, Kurt ^c   Wagner, Kenneth F ^c  

^a US ARMY MEDICAL RESEARCH INSTITUTE OF CHEMICAL DEFENSE   (United States)

^b ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

^d Walter Reed Army Medical Center ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 160; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS ANTIGEN;

ADULT; ARTICLE; BACULOVIRUS; CELL INFILTRATION; CLINICAL ARTICLE; CLINICAL TRIAL; DELAYED HYPERSENSITIVITY; EOSINOPHILIA; FEMALE; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IMMUNE COMPLEX DEPOSITION; LEPIDOPTERA; MALE; MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; SKIN BIOPSY; SKIN MANIFESTATION; T LYMPHOCYTE ACTIVATION; VACCINATION;

ADULT; AIDS VACCINES; FEMALE; HIV ENVELOPE PROTEIN GP160; HIV INFECTIONS; HIV-1; HUMANS; HYPERSENSITIVITY, DELAYED; MALE; SKIN; T-LYMPHOCYTES; VACCINATION;

EID: 0031979446     PISSN: 00119059     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-4362.1998.00272.x     Document Type: Article

References (28)

1. Bolognesi DP. The immune response to HIV: implications for vaccine development. Semin Imtmtnol 1993; 5: 2,03114.
2. Feinberg MB, Greene WC. Molecular insights into human immunodeficiency virus type I pathogenesis. Curr Opin Immitnol 1992.; 4: 466-474.
3. Oxford JS, Frezza P, Race E. Challenges and strategies for AIDS vaccine development. Vaccine 1993; n: 612-614.
4. Verani P, Butto S, Taddeo B, et al. HIV variability and perspectives for a vaccine. Vaccine 1993; II: 542-544.
5. Levy JA. Pathogenesis of human immunodeficiency virus infection. Microbiol Rev 1993; 57: 183-189.
6. Shearer GM, Clerici M. Abnormalities of immune regulation in human immunodeficiency virus infection. Fed Res 1993; 33: 571-575.
7. Wolfs TRW, Nara PL, Goudsmit J. Genotypic and phenotypic variation of HIV-i: impact on AIDS pathogenesis and vaccination. Chem Immiinol 1993; 56: 1-33-
8. Pomerantz RJ, Bagasra O, Baltimore D. Cellular latency of human immunodeficiency virus type i. Curr Opin Immiinol 1991; 4: 475-480.
9. Philip RJ, McMichael AJ. How does the HIV escape cytotoxic T cell immunity? Chem Immiinol 1993; 56: 150-164.
10. IG Redfield RR, Birx DL, Ketter N, et al. A Phase I evaluation of the safety and immunogenicity of vaccination with recombinant gpi6o in patients with early human immunodeficiency virus infection. N Engt } Med 1991; 324: 1677-1684.
11. Dobin R, Graham B, Greenberg SB, et al. The safety and immunogenicity of human immunodeficiency virus type I (HIV-i) recombinant gpiéo candidate vaccine in humans. Ann Intern Med 1991; 114: 119-117.
12. Cominos D, Strutton G, Busmanis I. Granulomas associated with tetanus toxoid immunization. Am J Dermatopathol 1993; 15: 114-117.
13. Slater DN, Underwood JCE, Durrant TE, et al. Aluminum hydroxide granulonias: light and electron microscopic studies and x-ray microanalysis. Br } Dermatol 1982; 107: 103-108.
14. Akosa AB, Ali MH, Khoo CTK, Evans DM. Angiolymphoid hyperplasia with eosinophilia associated with tetanus toxoid vaccination. Histopathology 1990; 16: 589-593.
15. VaxSyn HIV-i (Human T-lymphotropic virus type III gpioo antigens, recombinant vaccine, aluminum phosphate absorbed (product information)). Meriden, CT: MicroGeneSys, Inc.
16. Geoghegan WD. Humoral mechanisms of skin disease. In Jordon RE, éd. Immunologie Diseases of the Skin. Norwalk, CT: Appleton & Lange, 1990: 37-50.
17. Muller KM, Rocken M, Carlberg C, Hauser C. The induction and functions of murine T-helper cell subsets. / Invest Dermatol 1995; 104: 88-138.
18. Muller KM, Jaunin F, Masouye I, et al. Involvement of granulocytes and the adhesion receptors intercellular adhesion molecule-i and lymphocyte function-associated antigen-i in tissue inflammation induced by Thi-type helper cells. / Invest Dermatol 1995; 104: 350-354.
19. Shearer GM, Clerici M. T helper cell immune dysfunction in symptomatic, HIV-i-seropositive individuals: the role of THi-THi cross-regulation. Chem Immunol 1992; 54: 21-43.
20. Mosemann TR, Coffman RL. Thi and Th.2 cells: different patterns of lymphokine secretion lead to different functional properties. Annn Rev Immunol 1989; 7: 145-173.
21. Romagnani S. Induction of Thi and Th.2 responses: a key role for the "natural" immune response? Immunol Today 1993; 14: 95-96.
22. Liew FY. Induction, regulation and function of T-cell subsets in Leishmaniasis. Chem Immunol 1992; 54: 117-135.
23. Cheng TL, Shea CM, Urioste S, et a Heterogeneity of IL-2, and IL-4 producing {Thi and Thz) clones to antigens presented by different accessory cells. J Immunol 1990; 145: 2803-2808.
24. Daynes RA, Arameeo BA, Dowell TA, et al. Regulation of murine lymphokine production in vivo. III. The lymphoid tissue microenvironment exerts regulatory influences over T helper cell function. / Exp Med 1990; 171: 979-996.
25. Yssel H, Shanafelt MC, Soderberg C, et al. Borrelia burgdorferi activates a T helper type i-like T cell subset in Lyme arthritis. / Exp Med 1991; 174: 593-601.
26. Delprete GF, DeCarli M, Mastromauro C, et al. Purified protein derivative of Mycobacteritim tuberculosis and excretory-secretory antigens of Toxocara canis expand in vitro human T cells with stable and opposite (Type i T helper or Type 2 T helper) profile of cytokine production. / Clin Invest 1991; 88: 346-350.
27. Smith KJ, Skelton HG, Yeager J, et al. Histologie features of foreign body reactions in HIV-I disease and their correlation with Walter Reed stage. J Am Acad Dermatol 1994; 28: 174-184.
28. Audibert FM, Lise LD. Adjuvants: current status, clinical perspectives and future prospects. Immunol Today 1993; 14: 281-284.